MDXG logo

MiMedx (MDXG) Company Overview

Profile

Full Name:

MiMedx Group, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

February 12, 2008

Indexes:

Not included

Description:

MiMedx Group, Inc. (MDXG) is a biotechnology company that develops and sells regenerative medicine products. They focus on healing wounds and treating various conditions using human placental tissue. Their innovative therapies aim to improve patient outcomes in healthcare settings.

Key Details

Price

$8.71

Annual Revenue

$321.48 M(+20.03% YoY)

Annual EPS

$0.37(+212.12% YoY)

Annual ROE

108.14%

Beta

0.74

Events Calendar

Earnings

Next earnings date:

Feb 28, 2025

Recent quarterly earnings:

Oct 30, 2024

Recent annual earnings:

Feb 28, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Apr 2, 2008

Analyst ratings

Recent major analysts updates

Aug 1, 24 Craig-Hallum
Buy
Aug 1, 24 Cantor Fitzgerald
Overweight
Jul 2, 24 Cantor Fitzgerald
Overweight
May 1, 24 HC Wainwright & Co.
Buy
Mar 7, 24 Lake Street
Buy
Mar 1, 24 Mizuho
Buy
Oct 31, 23 Mizuho
Buy
Oct 27, 23 Craig-Hallum
Buy
Aug 2, 23 Mizuho
Buy
Aug 2, 23 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Recent Price Trend in MiMedx (MDXG) is Your Friend, Here's Why
Recent Price Trend in MiMedx (MDXG) is Your Friend, Here's Why
Recent Price Trend in MiMedx (MDXG) is Your Friend, Here's Why
MDXG
zacks.comDecember 2, 2024

If you are looking for stocks that are well positioned to maintain their recent uptrend, MiMedx (MDXG) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Recent Price Trend in MiMedx (MDXG) is Your Friend, Here's Why
Recent Price Trend in MiMedx (MDXG) is Your Friend, Here's Why
Recent Price Trend in MiMedx (MDXG) is Your Friend, Here's Why
MDXG
zacks.comDecember 2, 2024

MiMedx (MDXG) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

MIMEDX's Advocacy to Rein in Runaway Medicare Spend for Skin Substitutes Has Yielded Significant Results with Planned Implementation of LCDs
MIMEDX's Advocacy to Rein in Runaway Medicare Spend for Skin Substitutes Has Yielded Significant Results with Planned Implementation of LCDs
MIMEDX's Advocacy to Rein in Runaway Medicare Spend for Skin Substitutes Has Yielded Significant Results with Planned Implementation of LCDs
MDXG
globenewswire.comNovember 14, 2024

Over 200 Unproven Skin Substitutes Will No Longer Be Covered Under Revised LCDs Company to Benefit from MACs' Commitment to Clinically Effective, Proven Products MARIETTA, Ga., Nov. 14, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today provided the following update on the Local Coverage Determinations (“LCDs”) regarding “Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers.

Can MiMedx (MDXG) Climb 77.92% to Reach the Level Wall Street Analysts Expect?
Can MiMedx (MDXG) Climb 77.92% to Reach the Level Wall Street Analysts Expect?
Can MiMedx (MDXG) Climb 77.92% to Reach the Level Wall Street Analysts Expect?
MDXG
zacks.comNovember 4, 2024

The consensus price target hints at a 77.9% upside potential for MiMedx (MDXG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

MiMedx (MDXG) Q3 Earnings and Revenues Surpass Estimates
MiMedx (MDXG) Q3 Earnings and Revenues Surpass Estimates
MiMedx (MDXG) Q3 Earnings and Revenues Surpass Estimates
MDXG
zacks.comOctober 30, 2024

MiMedx (MDXG) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to earnings of $0.05 per share a year ago.

MIMEDX to Host Third Quarter 2024 Operating and Financial Results Conference Call on October 30
MIMEDX to Host Third Quarter 2024 Operating and Financial Results Conference Call on October 30
MIMEDX to Host Third Quarter 2024 Operating and Financial Results Conference Call on October 30
MDXG
globenewswire.comOctober 14, 2024

MARIETTA, Ga., Oct. 14, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the third quarter ended September 30, 2024 after the market close on Wednesday, October 30, 2024. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day.

MIMEDX Points to The New York Times Article on the Vast Benefits of Placental Tissue
MIMEDX Points to The New York Times Article on the Vast Benefits of Placental Tissue
MIMEDX Points to The New York Times Article on the Vast Benefits of Placental Tissue
MDXG
globenewswire.comOctober 8, 2024

MARIETTA, Ga., Oct. 08, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today highlighted the publication of a feature article on placental allografts for patients with hard-to-heal, acute and chronic wounds, which was published in today's New York Times: “Her Face Was Unrecognizable After an Explosion.

MIMEDX Showcases Leading Allograft Portfolio and Its Latest Scientific and Clinical Evidence at SAWC Fall
MIMEDX Showcases Leading Allograft Portfolio and Its Latest Scientific and Clinical Evidence at SAWC Fall
MIMEDX Showcases Leading Allograft Portfolio and Its Latest Scientific and Clinical Evidence at SAWC Fall
MDXG
globenewswire.comOctober 1, 2024

Company to Sponsor Lunch Symposium and Hands-On Skills Lab Featuring Seven Accepted Posters, Further Expanding Its Best-In-Class Portfolio of Clinical and Scientific Research   MARIETTA, Ga., Oct. 01, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced its schedule for the Symposium on Advanced Wound Care (SAWC) Fall meeting taking place October 2-5 in Las Vegas, NV.

THIRD DEFENDANT FIGHTS BACK AGAINST MiMEDX, CLAIMING 'DISREPUTABLE AND UNLAWFUL BUSINESS PRACTICES'
THIRD DEFENDANT FIGHTS BACK AGAINST MiMEDX, CLAIMING 'DISREPUTABLE AND UNLAWFUL BUSINESS PRACTICES'
THIRD DEFENDANT FIGHTS BACK AGAINST MiMEDX, CLAIMING 'DISREPUTABLE AND UNLAWFUL BUSINESS PRACTICES'
MDXG
prnewswire.comSeptember 4, 2024

Ex-MiMedx Employee Jake Heikkinen Files Counterclaims Alleging Schemes 'To Bilk Medicare' and 'Incentivize and Pressure Healthcare Providers' per Mintz Attorneys MARIETTA, Ga. , Sept. 4, 2024 /PRNewswire/ -- The third of 10 defendants who were sued earlier this year by MiMedx Group, Inc. (NASDAQ: MDXG) today filed counterclaims against the company.

DEFENDANT FIGHTS BACK AGAINST MiMEDX "BLATANT INTIMIDATION" NON-COMPETE SUIT
DEFENDANT FIGHTS BACK AGAINST MiMEDX "BLATANT INTIMIDATION" NON-COMPETE SUIT
DEFENDANT FIGHTS BACK AGAINST MiMEDX "BLATANT INTIMIDATION" NON-COMPETE SUIT
MDXG
prnewswire.comAugust 26, 2024

Ex-MiMedx Employee Caralyn Gargan Files Counterclaims for "Predatory Sales Practices" and "Incentivized Fraud" per Mintz Attorneys MARIETTA, Ga. , Aug. 26, 2024 /PRNewswire/ -- One of 10 defendants who were sued earlier this year by MiMedx Group, Inc. (NASDAQ: MDXG) today filed counterclaims against the placental biologics company.

  • 1(current)
  • 2
  • 1(current)
  • 2

FAQ

  • What is the ticker symbol for MiMedx?
  • Does MiMedx pay dividends?
  • What sector is MiMedx in?
  • What industry is MiMedx in?
  • What country is MiMedx based in?
  • When did MiMedx go public?
  • Is MiMedx in the S&P 500?
  • Is MiMedx in the NASDAQ 100?
  • Is MiMedx in the Dow Jones?
  • When was MiMedx's last earnings report?
  • When does MiMedx report earnings?
  • Should I buy MiMedx stock now?

What is the ticker symbol for MiMedx?

The ticker symbol for MiMedx is NASDAQ:MDXG

Does MiMedx pay dividends?

No, MiMedx does not pay dividends

What sector is MiMedx in?

MiMedx is in the Healthcare sector

What industry is MiMedx in?

MiMedx is in the Biotechnology industry

What country is MiMedx based in?

MiMedx is headquartered in United States

When did MiMedx go public?

MiMedx's initial public offering (IPO) was on February 12, 2008

Is MiMedx in the S&P 500?

No, MiMedx is not included in the S&P 500 index

Is MiMedx in the NASDAQ 100?

No, MiMedx is not included in the NASDAQ 100 index

Is MiMedx in the Dow Jones?

No, MiMedx is not included in the Dow Jones index

When was MiMedx's last earnings report?

MiMedx's most recent earnings report was on Oct 30, 2024

When does MiMedx report earnings?

The next expected earnings date for MiMedx is Feb 28, 2025

Should I buy MiMedx stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions